Stage at diagnosis and stage-specific survival of breast cancer in Latin America and the Caribbean: A systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
12
2018
accepted:
03
10
2019
entrez:
17
10
2019
pubmed:
17
10
2019
medline:
17
3
2020
Statut:
epublish
Résumé
Female breast cancer is the most common cancer in Latin American and Caribbean (LAC) countries and is the leading cause of cancer deaths. The high mortality-to-incidence ratio in the regions is associated with mainly the high proportion of advanced stage diagnosis, and also to inadequate access to health care. In this study we aimed to systematically review the proportion of advanced stage (III-IV) at diagnosis (pas) and the five-year stage-specific survival estimates of breast cancer in LAC countries. We searched MEDLINE, Embase, and LILACS (Latin American and Caribbean Health Science Literature) to identify studies, in any language, indexed before Nov 5, 2018. We also conducted manual search by reviewing citations of papers found. pas was summarized by random effects model meta-analysis, and meta-regression analysis to identify sources of variation. Stage-specific survival probabilities were described as provided by study authors, as it was not possible to conduct meta-analysis. PROSPERO CRD42017052493. For pas we included 63 studies, 13 of which population-based, from 22 countries comprising 221,255 women diagnosed from 1966 to 2017. The distribution of patients by stage varied greatly in LAC (pas 40.8%, 95%CI 37.0% to 44.6%; I2 = 99%; p<0.0001). The heterogeneity was not explained by any variable included in the meta-regression. There was no difference in pas among the Caribbean (pas 43.0%, 95%CI 33.1% to 53.6%), Central America (pas 47.0%, 95%CI 40.4% to 53.8%) and South America (pas 37.7%, 95%CI 33.1% to 42.5%) regions. For 5-year stage-specific survival we included 37 studies, comprising 28,988 women from ten countries. Seven of these studies were included also for pas. Since we were unable to adjust for age, comparability between countries and regions was hampered, and as expected, the results varied widely from study to study. LAC countries should look to address concerns with early detection and diagnosis of breast cancer, and wherever viable implement screening programs and to provide timely treatment.
Sections du résumé
BACKGROUND
Female breast cancer is the most common cancer in Latin American and Caribbean (LAC) countries and is the leading cause of cancer deaths. The high mortality-to-incidence ratio in the regions is associated with mainly the high proportion of advanced stage diagnosis, and also to inadequate access to health care. In this study we aimed to systematically review the proportion of advanced stage (III-IV) at diagnosis (pas) and the five-year stage-specific survival estimates of breast cancer in LAC countries.
METHODS
We searched MEDLINE, Embase, and LILACS (Latin American and Caribbean Health Science Literature) to identify studies, in any language, indexed before Nov 5, 2018. We also conducted manual search by reviewing citations of papers found. pas was summarized by random effects model meta-analysis, and meta-regression analysis to identify sources of variation. Stage-specific survival probabilities were described as provided by study authors, as it was not possible to conduct meta-analysis. PROSPERO CRD42017052493.
RESULTS
For pas we included 63 studies, 13 of which population-based, from 22 countries comprising 221,255 women diagnosed from 1966 to 2017. The distribution of patients by stage varied greatly in LAC (pas 40.8%, 95%CI 37.0% to 44.6%; I2 = 99%; p<0.0001). The heterogeneity was not explained by any variable included in the meta-regression. There was no difference in pas among the Caribbean (pas 43.0%, 95%CI 33.1% to 53.6%), Central America (pas 47.0%, 95%CI 40.4% to 53.8%) and South America (pas 37.7%, 95%CI 33.1% to 42.5%) regions. For 5-year stage-specific survival we included 37 studies, comprising 28,988 women from ten countries. Seven of these studies were included also for pas. Since we were unable to adjust for age, comparability between countries and regions was hampered, and as expected, the results varied widely from study to study.
CONCLUSIONS
LAC countries should look to address concerns with early detection and diagnosis of breast cancer, and wherever viable implement screening programs and to provide timely treatment.
Identifiants
pubmed: 31618268
doi: 10.1371/journal.pone.0224012
pii: PONE-D-18-35785
pmc: PMC6799865
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0224012Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Cancer. 2009 Jan 1;124(1):174-9
pubmed: 18814239
Cancer Manag Res. 2018 Oct 30;10:4899-4914
pubmed: 30464592
Breast. 2011 Apr;20 Suppl 2:S54-9
pubmed: 21371885
IARC Sci Publ. 2011;(162):85-8
pubmed: 21675408
Rev Bras Ginecol Obstet. 2009 Feb;31(2):75-81
pubmed: 19407912
BMC Cancer. 2012 Mar 29;12:122
pubmed: 22455370
Salud Colect. 2013 Apr;9(1):79-90
pubmed: 23680751
Lancet Glob Health. 2016 Dec;4(12):e923-e935
pubmed: 27855871
Lancet. 2015 Mar 28;385(9974):1230-47
pubmed: 25458725
Rev Saude Publica. 2017 Jun 01;51(suppl 1):14s
pubmed: 28591356
Br J Cancer. 2013 Mar 19;108(5):1195-208
pubmed: 23449362
IARC Sci Publ. 1998;(145):51-9
pubmed: 10194627
IARC Sci Publ. 2011;(162):89-95
pubmed: 21675409
J Epidemiol. 2017 Jul;27(7):299-304
pubmed: 28279589
Front Public Health. 2014 Jul 29;2:87
pubmed: 25121080
Breast Cancer (Auckl). 2018 Jan 08;12:1178223417752677
pubmed: 29434475
Am Soc Clin Oncol Educ Book. 2018 May 23;38:451-456
pubmed: 30231404
J Gynecol Oncol. 2018 May;29(3):e44
pubmed: 29533026
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Oncologist. 2013;18(3):248-56
pubmed: 23442305
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Ginecol Obstet Mex. 2016 Aug;84(8):498-506
pubmed: 29424511
Breast Cancer (Auckl). 2016 Apr 21;10:45-52
pubmed: 27127408
Cancer. 2008 Oct 15;113(8 Suppl):2359-65
pubmed: 18837031
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Lancet Oncol. 2013 Apr;14(5):391-436
pubmed: 23628188
N Engl J Med. 1985 Jun 20;312(25):1604-8
pubmed: 4000199
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
PLoS Med. 2014 Sep 09;11(9):e1001720
pubmed: 25202974
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Detect Prev. 2003;27(6):466-71
pubmed: 14642555
JAMA Oncol. 2016 Mar;2(3):322-9
pubmed: 26659132
J Natl Cancer Inst. 2013 Oct 2;105(19):1456-62
pubmed: 23940288
Rev Assoc Med Bras (1992). 2015 Sep-Oct;61(5):411-6
pubmed: 26603003